Thursday, May 26, 2022 12:34:12 PM
https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-29-november-2021/freedom-of-information-request-on-the-recent-inspection-of-the-results-for-advent-bioservices-completed-inspection-foi-211233
FOI release
Freedom of Information request on the recent inspection of the results for Advent Bioservices completed inspection (FOI 21/1233)
Published 26 May 2022
FOI 21/1233
1st December 2021
Dear,
Thank you for your communication to the MHRA in relation to a Freedom of Information request for:
1. Information on the recent inspection of the results for Advent Bioservices completed inspection.
2. Could you please point me towards where I may find this information? Where may I find the authorization number, or what the site name is listed under?
1.We would like to inform you that the inspection findings are currently subject to an on-going regulatory procedure, in that the inspection has not been closed out, therefore the information that you have requested currently cannot be disclosed.
Under the Freedom of Information Act (FOIA) certain exemptions apply to the information we can make available and this report request is subject to exemptions contained in the FOIA, namely section 30:
“Investigations and Proceedings Conducted by Public Authorities”
The report will be available when this procedure has reached its conclusion.
2.The information is exempt under Section 21 of the Freedom of Information Act (FOIA), because the information is accessible to you, as it is already in the public domain.
https://cms.mhra.gov.uk/mhra
https://www.gov.uk/government/collections/licences-to-manufacture-or-wholesale-in-medicines
We have considered the balance of the public interest when applying this exemption. The exemption is to ensure that the regulatory authority is able to carry out it’s statutory functions efficiently, fairly, unimpeded and confidentially. Releasing confidential details into the public domain would have the effect of alerting the subject to aspects of an ongoing investigation about them and giving them forewarning to take evasive action. It would also be unfair in cases where the subject of the investigation was either found not to be in breach of legislation or was able to bring themselves into compliance without the need for any legal sanctions to be applied, thus potentially damaging their reputation. In this case I have not identified any issues which would benefit the public as a whole by being brought to their attention (examples of issues would be a major public health risk or a major procedural failure or irregularity) .
If you have a query about this letter, please do not hesitate to contact us at IE&SFOI@mhra.gov.uk
If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please email: info@mhra.gov.uk
Due to the ongoing Covid-19 situation, we are not able to accept delivery of any documents or correspondence by post or courier to any of our offices.
After that, if you remain dissatisfied, you may write to the Information Commissioner at;
The Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Yours sincerely
IE&S FOI Team
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
